Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers.
The cover for issue 1 of Oncotarget features Figure 2, "Results in clinical trials," published in "Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer" by Blagoev, et al. which reported that most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered.
When compared to other groups, certain ethnic and racial groups tend to suffer more often, and fare worse, from common ailments.
Cancer cells are known for spreading genetic chaos. As cancer cells divide, DNA segments and even whole chromosomes can be duplicated, mutated, or lost altogether.
A researcher at the University of Tartu described new associations between Neandertal DNA and autoimmune diseases, prostate cancer and type 2 diabetes.
Opened in 2016, Manchester’s Stoller Biomarker Discovery Centre (SBDC) is a globally renowned, multi-million-pound precision medicine research facility.
Researchers at the Estonian Genome Center at the University of Tartu studied how people at high risk for breast, ovarian or prostate cancer respond to the feedback of genetic findings.
Scientists have used metal-organic frameworks to effectively deliver the CRISPR/Cas9 genetic snipping tool into human cancer cells.
Researchers have identified a genetic signature in localized prostate cancer that can predict whether the cancer is likely to spread, or metastasize, early in the course of the disease and whether it will respond to anti-androgen therapy, a common treatment for advanced disease.
Unrelated mutations, when present in the blood, can lead to false positive results in men with advanced prostate cancer who are undergoing liquid biopsies.
Scientists have shown that cancer rebuilds the architecture of human chromosomes, which allows the disease to take hold and spread.
Focusing ultrasound energy on a target site in the body to generate heat can burn and destroy the tissue in the site without a surgical procedure.
Although a recent campaign by Cancer Research UK emphasized obesity as a risk factor for cancer on par with smoking, the scientific literature on the relationship between increased weight and cancer risk is not so clear.
Prostate cancer is the most common type of cancer among American men after skin cancer, but the disease does not affect all races equally.
Rutgers researchers have discovered human gene markers that work together to cause metastatic prostate cancer - cancer that spreads beyond the prostate.
According to a new study reported in the Oncogene journal, the thymoquinone (TQ) compound selectively destroys prostate cancer cells at advanced phases.
Multiparametric magnetic resonance imaging of the prostate (mpMRIp) is a promising tool for diagnosing prostate cancer, and prior to its availability, detection relied on clinical exams and prostate specific antigen screening.
Using specialized nanoparticles, MIT engineers have developed a way to turn off specific genes in cells of the bone marrow, which play an important role in producing blood cells.
New research shows how the gut microbiome communicates with an oral drug in prostate cancer patients.
PIM kinases are essentially enzymes that support the metastatic growth and proliferation of tumor cells.